---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-033894"
form_type: "8-K"
ticker: "VCEL"
cik: "0000887359"
company_name: "Vericel Corp"
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T14:10:11.224539+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vericel Q2 revenue rises 15% to $52.7M; MACI up 21%; raises FY2024 margin guidance to 71%

## Summary
- MACI net revenue $44.1M (+21% YoY); NexoBrid revenue $0.8M (+76% QoQ); Burn Care franchise total $8.5M.
- Gross margin 70% (up 430bps); adjusted EBITDA $6.3M (+42%), margin 12% (up 230bps).
- FY2024 guidance reaffirmed: revenue $238-242M; gross margin raised to 71%, adjusted EBITDA margin to 21%.
- MACI Arthro launch expected later Q3 2024; NexoBrid pediatric FDA approval anticipated in Q3 2024.
- Net loss $4.7M ($0.10 diluted EPS) vs $5.0M loss in prior year; cash $154M, no debt.

## SEC filing metadata
- accession: 0001628280-24-033894
- form_type: 8-K
- ticker: VCEL
- cik: 0000887359
- company_name: Vericel Corp
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887359/000162828024033894/0001628280-24-033894-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887359/000162828024033894/vcel-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-033894
- JSON: https://secwatch.observer/filing/0001628280-24-033894.json
- Plain text: https://secwatch.observer/filing/0001628280-24-033894.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.